Quality & complianceOfficial

Wedgewood Pharmacy recalls in-expiry compounded veterinary drugs over unreliable laboratory testing data

🇺🇸 FDA recalls · Wed 21 Oct 2026

The New Jersey compounder says analytical data from its own laboratory were inconsistent, so affected products may be subpotent or superpotent; 98 complaints have been received, 7 of them serious.

Wedgewood Pharmacy LLC, based in Swedesboro, New Jersey, announced on 21 October 2026 that it is recalling certain compounded veterinary medications that are still within expiry. The recall is at provider and customer level and was published by the US Food and Drug Administration the same day.

The company cites inconsistencies in the reliability of some analytical testing data generated by its laboratory. As a result, products may be subpotent, superpotent or both. Wedgewood says its own quality processes uncovered the problem, and that the recall is being carried out with the FDA's knowledge.

Affected products were shipped between 18 February and 6 October 2026 to veterinary practices, pharmacies and other customers across the US. The range covers powders, pastes, oral suspensions, injectables, ophthalmic ointments and solutions, ear solutions and suspensions, topical sprays and gels. Lot numbers and expiry dates are listed in a lookup tool on Wedgewood's website. The medicines are meant for companion, equine, exotic, zoo, wildlife and aquatic animals, not food-producing animals.

Wedgewood describes the hazards as ineffective treatment from low potency and possible toxicity or overdose from high potency. To date it has received 98 complaints, 7 of which it classes as serious. It has engaged Sedgwick to coordinate the recall, notify customers by email and post, and arrange refunds or, where possible, replacements.

Businesses are told to check inventory, quarantine affected product and contact the recall line. Practices and pharmacies that have already dispensed product must identify and notify their own customers. Animal owners should stop use, keep the product and phone the recall line, and should speak to their veterinarian if they have medical concerns. Adverse reactions or quality problems can be reported to the FDA.

What it means for your team

  • Quality teams should review data-integrity and analytical testing controls at compounding pharmacies and contract laboratories in their supply chains.
  • Veterinary pharmacovigilance teams should expect potency-related adverse event reports, covering both lack of efficacy and toxicity or overdose, linked to the affected lots.
  • Practices and pharmacies that have dispensed the products need a documented process for tracing lots and notifying downstream customers.
  • Affected sites should quarantine stock and use the company's lot lookup to confirm which products are involved.

Official source: FDA recalls ↗

Article written by VigiEye from the official source (FDA recalls). AI-assisted; check the source before acting.

More Quality & compliance All →